[ Pobierz całość w formacie PDF ]
problem of drug design. J Med Chem 17:533 287. Klepper J, Salas-Burgos A, Gertsen E, Fischbarg
535. J. 2005. Bench meets bedside: A 10-year-old girl
273. Hou TJ, Xu XJ. 2003. ADME evaluation in drug and amino acid residue glycine 75 of the facilita-
discovery. 3. Modeling blood-brain barrier parti- tive glucose transporter Glut1. Biochemistry
tioning using simple molecular descriptors. 44:12621 12626.
J Chem Inf Comput Sci 43:2137 2152. 288. Boado RJ, Li JY, Nagaya M, Zhang C,
274. Ajay Bemis GW, Murcko MA. 1999. Designing Pardridge WM. 1999. Selective expression of
libraries with CNS activity. J Med Chem 42: the large neutral aminoacid transporter at the
4942 4951. blood-brain barrier. Proc Natl Acad Sci 12:
275. Kang YS, Terasaki T, Tsuji A. 1990. Acidic drug 12079 12084.
transport in-vivo through the blood-brain barrier: 289. Pardridge WM. 2003. Blood-brain barrier geno-
A role of the transport carrier for monocarboxylic mics and the use of endogenous transporters to
acids. J Pharmacobiodyn 13:158 163. cause drug penetration into the brain. Curr Opin
276. Tsuji A. 2005. Small molecular drug transfer Drug Discov Dev 6:683 691.
across the blood-brain barrier via carrier- 290. Pardridge WM. Brain drug targeting and gene
mediated transport systems. NeuroRx 2:54 62. technologies. Jpn J Pharmacol 87:97 103.
277. Cornford EM, Oldendorf WH. 1975. Independent 291. Cecchelli R, Berezowski V, Lundquist S, Culot M,
blood-brain barrier transport systems for nucleic Renftel M, Dehouck MP, Fenart L. 2007. Modelling
acid precursors. Biochim Biophys Acta 394:210 of the blood-brain barrier in drug discovery and
211. development. Nature Rev Drug Discov 6:650 661.
278. Pardridge WM, Yoshikawa T, Kang YS, Miller LP. 292. Löscher W, Potschka H. 2005. Blood-brain barrier
1994. Blood-brain barrier transport and brain active efflux transporters: ATP-binding cassette
metabolism of adenosine and adenosine analogs. gene family. NeuroRx 2:86 98.
J Phamacol Exp Ther 268:14 18. 293. Löscher W, Potschka H. 2005. Role of drug efflux
279. Li JY, Boado RJ, Pardridge WM. 2001. Cloned transporters in the brain for drug disposition and
blood-brain barrier adenosine transporter is iden- treatment of brain diseases. Prog Neurobiol 76:
tical to the rat concentrative Naþ nucleoside 22 76.
cotransporter CNT2. J Cereb Blood Flow Metab 294. El Ela AA, Härtter S, Schmitt U, Hiemke C,
21:929 936. Spahn-Langguth H, Langguth P. 2004. Identifica-
280. Pardridge WM. 2003. Blood-brain barrier drug tion of P-glycoprotein substrates and inhibitors
targeting: The future of brain drug development. among psychoactive compounds. Implications for
Mol Interv 3:90 105. pharmacokinetics of selected substrates. Pharm
281. Pardridge WM. 2005. The blood-brain barrier: Pharmacol 56:967 975.
Bottleneck in brain drug development. NeuroRx 295. Golden PL, Pollack GM. 2003. Blood-brain barrier
2:3 14. efflux transport. J Pharm Sci 92:1739 1753.
282. Allen DD, Lockman PR. 2003. The blood-brain 296. Seelig A, Landwojtowicz E. 2000. Structure-activ-
barrier choline transporter as a brain drug deliv- ity relationship of P-glycoprotein substrates and
ery vector. Life Sci 73:1609 1615. modifiers. Eur J Pharm Sci 12:31 40.
283. Geldenhuys WJ, Lockman PR, McAfee JH, Fitz- 297. Wiese M, Pajeva IK. 2001. Structure-activity rela-
patrick KT, Van der Schyf CJ, Allen DD. 2004. tionships of multidrug resistance reservers. Curr
Molecular modeling studies on the active binding Med Chem 8:685 713.
site of the blood-brain barrier choline transporter. 298. Avendaño C, Menendez JC. 2002. Inhibitors of
Bioorg Med Chem Lett 14:3085 3092. multidrug resistance to antitumor agents
284. Geldenhuys WJ, Lockman PR, Nguyen TH, Van (MDR). Curr Med Chem 9:159 193.
der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD. 299. Pleban K, Ecker GF. 2005. Inhibitors of P-glyco-
2005. 3D-QSAR study of bis-azaaromatic quatern- protein Lead identification and optimization.
ary ammonium analogs at the blood-brain barrier Mini Rev Med Chem 5:153 163.
choline transporter. Bioorg Med Chem Lett 15: 300. Terasaki T, Hosoya K. 1999. The blood-brain bar-
4253 4261. rier efflux transporters as a detoxifying system for
285. Chang C, Ray A, Swaan P. 2005. In-silico strate- the brain. Adv Drug Deliv Rev 36:195 209.
gies for modeling membrane transporter function. 301. Ekins S. 2004. Predicting undesirable drug inter-
Drug Discov Today 10:663 671. actions with promiscuous proteins in-silico. Drug
286. Allen DD, Geldenhuys WJ. 2006. Molecular mod- Discov Today 9:276 285.
elling of blood-brain barrier nutrient transporters: 302. Recanatini M, Bottegoni G, Cavalli A. 2004. In-
In-silico basis for evaluation of potential drug silico antitarget screening. Drug Discov Today
Technol 1:209 215.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 12, DECEMBER 2009
4468 MENSCH ET AL.
303. Didziapetris R, Japertas P, Avdeef A, Petrauskas transport for diagnosis and treatment of brain
A. 2003. Classificatino analysis of P-glycoprotein disorders. Patent, PCT Int. Appl. 154pp. WO
substrate specificity. J Drug Target 11:391 2008022349 A2.
406. 310. Pardridge WM. 2006. Molecular Trojan horses
304. Penzotti JE, Lamb ML, Evensen E, Grootenhuis for blood-brain barrier drug delivery. Curr Opin
PDJ. 2002. A computational ensemble pharmaco- Pharmacol 6:494 500.
phore model for identifying substrates of P-glyco- 311. Pardridge WM. 2007. Drug targeting to the brain.
protein. J Med Chem 45:1737 1740. Pharm Res 24:1733 1744.
305. Xue Y, Yap CW, Sun LZ, Cao ZW, Wang JF, Chen 312. Pardridge WM. 2008. Re-engineering biopharma-
YZ. 2004. Prediction of P-glycoprotein substrates ceuticals for delivery to brain with molecular Tro-
by a support vector machine approach. J Chem Inf jan horses. Bioconj Chem 19:1327 1338.
[ Pobierz całość w formacie PDF ]